Haemonetics Corporation 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Haemonetics Corporation on March 3, 2025. The filing discloses significant executive leadership changes and compensatory arrangements effective in April 2025 and immediately.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on personnel appointments and compensation terms.
Material Changes
- Appointment of Executive Vice President, Chief Operating Officer: Frank W. Chan, Ph.D., will assume this role effective April 7, 2025. He will oversee research and development, regulatory affairs, and global manufacturing and supply chain functions, reporting to CEO Christopher A. Simon.
- Promotion of Executive Vice President, Chief Commercial Officer: Roy Galvin was promoted from President, Global Plasma and Blood Center, to Executive Vice President, Chief Commercial Officer, effective immediately. His role now encompasses the Global Hospital business and Global Plasma and Blood Center businesses.
- Transition of Global Hospital Leadership: Stewart Strong, President, Global Hospital, will continue in his role through April 1, 2025, after which he will serve as an advisor to the CEO to support the transition.
Compensation and Management Commentary
Management highlighted Mr. Chan's 25+ years of experience in the medical device sector, including recent leadership at Medtronic. The filing details the following compensation package for Mr. Chan:
- Base Salary: $550,000 annually.
- Short-Term Incentive: Target bonus of 80% of base salary ($440,000) based on fiscal 2026 financial metrics and individual performance.
- Long-Term Incentive: Equity award with a target value of $1,600,000 for fiscal 2026, subject to Compensation Committee approval.
- Sign-On Bonus: $350,000 payable after 60 days of employment. This includes a clawback provision: $300,000 is repayable if terminated voluntarily or for cause within the first 12 months, and $150,000 is repayable if terminated voluntarily or for cause between months 12 and 24.
- Other Agreements: Mr. Chan will enter into standard executive severance, change in control, and indemnification agreements consistent with the company's 2024 proxy statement.
Investor Verification Checklist
- Verify the effective date of Frank W. Chan's appointment (April 7, 2025) and Roy Galvin's promotion (immediate).
- Review the specific fiscal 2026 financial metrics tied to Mr. Chan's short-term incentive bonus.
- Confirm the terms of the standard severance and change in control agreements referenced in the 2024 proxy statement.
- Monitor the transition timeline for Stewart Strong's role as advisor post-April 1, 2025.